Related Experiment Videos

Physical barriers to drug delivery in tumors

¹National Cancer Institute-Frederick Cancer Research and Development Center, Division of Cancer Treatment, MD 21701.

Critical Reviews in Oncology/Hematology

|February 1, 1993

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Five-year survival with tebentafusp in metastatic uveal melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.

Blood·2001

Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.

Cancer journal (Sudbury, Mass.)·2000

Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.

The cancer journal from Scientific American·2000

Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.

Clinical immunology (Orlando, Fla.)·1999

Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.

Blood·1999

See all related articles